These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28376080)

  • 1. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
    Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S
    Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
    Hurt CN; Mukherjee S; Bridgewater J; Falk S; Crosby T; McDonald A; Joseph G; Staffurth J; Abrams RA; Blazeby JM; Bridges S; Dutton P; Griffiths G; Maughan T; Johnson C
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):810-8. PubMed ID: 26530749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
    Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
    Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
    Strauss VY; Shaw R; Virdee PS; Hurt CN; Ward E; Tranter B; Patel N; Bridgewater J; Parsons P; Radhakrishna G; O'Neill E; Sebag-Montefiore D; Hawkins M; Corrie PG; Maughan T; Mukherjee S
    BMC Cancer; 2019 Feb; 19(1):121. PubMed ID: 30717707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
    Mukherjee S; Qi C; Shaw R; Jones CM; Bridgewater JA; Radhakrishna G; Patel N; Holmes J; Virdee PS; Tranter B; Parsons P; Falk S; Wasan HS; Ajithkumar TV; Holyoake D; Roy R; Scott-Brown M; Hurt CN; O'Neill E; Sebag-Montefiore D; Maughan TS; Hawkins MA; Corrie P
    Eur J Cancer; 2024 Sep; 209():114236. PubMed ID: 39059185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
    Willenbrock F; Cox CM; Parkes EE; Wilhelm-Benartzi CS; Abraham AG; Owens R; Sabbagh A; Jones CM; Hughes DLI; Maughan T; Hurt CN; O'Neill EE; Mukherjee S
    Br J Cancer; 2021 Feb; 124(3):581-586. PubMed ID: 33100327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
    J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
    Faisal F; Tsai HL; Blackford A; Olino K; Xia C; De Jesus-Acosta A; Le DT; Cosgrove D; Azad N; Rasheed Z; Diaz LA; Donehower R; Laheru D; Hruban RH; Fishman EK; Edil BH; Schulick R; Wolfgang C; Herman J; Zheng L
    Am J Clin Oncol; 2016 Feb; 39(1):18-26. PubMed ID: 24351782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
    Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
    Sherman WH; Hecht E; Leung D; Chu K
    Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
    Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
    Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.